5% of MRSA patients in U.S. died

One of every 20 (or 5 percent) of the roughly 368,600 patients treated in U.S. hospitals in 2005 for Methicillin-resistant staphylococcus aureus, or MRSA, died, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

Most of the patients who died of this highly dangerous antibiotic resistant staph infection were elderly or low income.

The death rate for hospitalized MRSA patients was higher than the 4 percent death rate for hospitalized tuberculosis patients, another potentially deadly illness.

AHRQ also found that:

  • Approximately 332 Medicare patients per 100,000 were hospitalized for MRSA compared to 184 Medicaid patients and 29 patients with private insurance. The rate for uninsured patients was 43 admissions per 100,000 people.
  • Men were more likely to be hospitalized for MRSA (107 admissions per 100,000) than were women (92 admissions).
  • People in the South were 27 percent more likely (113 admissions per 100,000) to be hospitalized for MRSA than those in the Northeast and Midwest (89 admissions per 100,000 population). People in the West fell in between (96 admissions per 100,000).

This AHRQ News & Numbers summary is based on data in Infections with Methicillin-Resistant Staphylococcus Aureus (MRSA) in U.S. Hospitals, 1993-2005, Statistical Brief No. 35 (http://www.hcup-us.ahrq.gov/reports/statbriefs/sb35.jsp). The report uses statistics from the Nationwide Inpatient Sample, a database of hospital inpatient stays that is nationally representative of inpatient stays in all short-term, non-Federal hospitals. The data are drawn from hospitals that comprise 90 percent of all discharges in the United States and include all patients, regardless of insurance type, as well as the uninsured.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New roadmap to advance UK’s bioelectronics for healthcare through materials innovation